Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Sarcoma 23Lymphoma 16Osteosarcoma 11Lymphoma, Large B-Cell, Diffuse 11Hodgkin Disease 11Testicular Neoplasms 10Lymphoma, Non-Hodgkin 10Teratoma 8Ovarian Neoplasms 7Testicular Germ Cell Tumor 6Neuroectodermal Tumors, Primitive, Peripheral 6Neoplasms 6Burkitt Lymphoma 6Recurrence 5Endodermal Sinus Tumor 5Central Nervous System Neoplasms 5Carcinoma, Embryonal 5Lymphoma, Large-Cell, Anaplastic 4Seminoma 3Rhabdomyosarcoma 3Precursor Cell Lymphoblastic Leukemia-Lymphoma 3Ovarian Germ Cell Cancer 3Neurofibrosarcoma 3Lymphoma, Mantle-Cell 3Lymphoma, B-Cell 3Histiocytoma, Malignant Fibrous 3Fibrosarcoma 3Vomiting 2Sarcoma, Synovial 2Sarcoma, Alveolar Soft Part 2

Interventions

Brentuximab Vedotin 13fludarabine 8Cyclophosphamide 8Rituximab 6ruxolitinib 5fludarabine phosphate 5Melphalan 5Lenalidomide 5ponatinib 4Dexamethasone 4Busulfan 4Bortezomib 4nilotinib 3Whole-Body Irradiation 3Vincristine 3Prednisone 3Mycophenolic Acid 3Imatinib Mesylate 3Doxorubicin 3Bendamustine Hydrochloride 3Alemtuzumab 3vosaroxin 2pomalidomide 2Tacrolimus 2Sugars 2Stem Cell Transplantation 2Sirolimus 2Ondansetron 2Leukapheresis 2Granulocyte Colony-Stimulating Factor 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Hematologic Diseases × Ifosfamide × Clear all
NCT02592876 2019-05-17

Treatment Study of Denintuzumab Mafodotin (SGN-CD19A) Plus RICE Versus RICE Alone for Diffuse Large B-Cell Lymphoma

Seagen Inc.

Phase 2 Terminated
81 enrolled 15 charts
Lymphoid

Hematologic Diseases, Immune System Diseases, Immunoproliferative Disorders, Lymphatic Diseases, Lymphoma, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Neoplasms, Neoplasms by Histologic Type, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse

Data powered by HemOnc (CC BY 4.0) Colophon âš¡